Eli Lilly developed the diabetes drug Mounjaro and sells it under the brand Zepbound for obesity.
Eli Lilly and Company markets tirzepatide under two brand names. Mounjaro is approved for improving blood-sugar control in adults with type 2 diabetes, while Zepbound is approved in the United States for chronic weight management in eligible adults and, in specified circumstances, adolescents.
Tirzepatide is a once-weekly injectable medicine that activates receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Those biological effects can influence blood sugar, appetite, and body weight. The brand names refer to the same active ingredient but different approved uses and labeling.
Eli Lilly was founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana. It is often confused with Novo Nordisk, another major diabetes and obesity-drug company, but Novo Nordisk developed semaglutide products such as Ozempic and Wegovy.